Biogen

Biogen is a biotechnology company focused on neurological and neurodegenerative diseases, including multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy, operating in one of the most computationally demanding areas of drug development due to the complexity of central nervous system biology. The company's engineering challenges include developing AI and ML platforms for neuroimaging analysis and biomarker discovery, building data pipelines that integrate clinical trial data with longitudinal patient datasets, and creating computational tools for understanding disease progression in conditions where biological mechanisms remain poorly characterized. Their technology organization supports neuroinformatics, digital biomarker development, clinical data management, and the enterprise systems required for a mid-cap biopharma company navigating a pipeline-driven growth strategy. Biogen's hiring patterns reflect the neuroscience sector's growing reliance on computational approaches, with demand for ML engineers, data scientists, and software engineers who can apply quantitative methods to some of the most challenging problems in drug development.